eMedicine Specialties > Plastic Surgery > Skin

Skin Malignancies, Melanoma

Author: Jonathan B Heistein, MD, Private Practice, Plastic and Reconstructive Surgery
Coauthor(s): Robert L Ruberg, MD, Chair, Professor, Department of Surgery, Division of Plastic Surgery, Ohio State University College of Medicine
Contributor Information and Disclosures

Updated: Sep 26, 2008

Introduction

History

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. Melanoma predominantly affects adults, with a peak incidence in the fourth decade, and has no sex prevalence. A patient's risk of developing a second primary melanoma after diagnosis of the first one is 3-5%.

Definition of problem

Melanoma poses an increasingly difficult problem as more people are affected. The incidence is estimated to be rising by almost 6% per year. Recognition of this disease as an entity is crucial so that people may seek medical attention while the tumor is still in its early stages, prior to metastasis. Efforts should be directed toward public awareness campaigns. For more information, see Medscape's Skin Cancer Resource Center and Melanoma Resource Center.

Frequency

In the United States, the incidence of melanoma continues to increase, with the prevalence of trunk and extremity lesions rising relatively faster than that of head and neck lesions; however, survival rates are improving. An estimated 34,100 people developed melanoma in the United States in 1995, with 7,200 deaths. This is an increase from the 27,600 new cases in 1990 and the 6,300 deaths. Furthermore, approximately 44,200 new melanoma diagnoses were made in 1999, and approximately 7,300 deaths were reported. An estimated 62,480 new cases of melanoma will occur in the United States in 2008, with 8,420 deaths.1 Currently, in the United States, approximately 1 in 50 white persons, 1 in 1,000 black persons, and 1 in 200 Hispanic persons develops melanoma at some point in his or her lifetime.1

Internationally, incidence varies worldwide. White populations in Australia, New Zealand, South Africa, and the southern United States have the highest rates, while Asian populations in Hong Kong, Singapore, China, India, and Japan have the lowest rates. This suggests that white persons who live in sunny areas are at significant risk.

Etiology/risk factors

  • Family history
    • Positive family history in 5-10% of patients
    • With at least one affected relative, 2.2-fold higher risk
  • Personal characteristics
    • Blue eyes, fair and/or red hair, pale complexion
    • Skin reaction to sunlight - Easily sunburned
    • Freckling
    • Benign and/or dysplastic melanocytic nevi - Number has better correlation than size
    • Immunosuppressive states - Transplantation patients, hematologic malignancies
  • Sun exposure during adolescence
    • High UV-B radiation
    • Low latitude
    • Number of blistering sunburns
  • Atypical mole syndrome (formerly termed B-K mole syndrome, dysplastic nevus syndrome, familial atypical multiple mole melanoma)
    • Over 10 years, 10.7% risk of melanoma (vs 0.62% of controls)
    • Higher risk of melanoma depending on number of family members affected (nearly 100% risk if 2 or more relatives have dysplastic nevi and melanoma)

Pathophysiology

Some researchers have suggested that benign melanocytic nevi are markers of melanoma risk rather than direct precursors; however, dysplastic nevi are believed to degenerate over time into melanoma. Lentigo maligna is believed to be a preinvasive precursor of lentigo maligna melanoma, and at least 5% progress to malignancy.2

Clinical presentation

Patients usually present with skin lesions that have changed in size, color, contour, or configuration. The acronym "ABCDE" is the hallmark of international public awareness campaigns and may be used to remember the physical characteristics suggestive of malignancy. ABCDE stands for asymmetry, irregular border, color variations (especially red, white, and blue tones in a brown or black lesion), diameter greater than 6 mm, and elevated surface. Lesions may itch, bleed, ulcerate, or develop satellites.

Perform excisional biopsy on these suggestive lesions so that a pathologist can confirm the diagnosis. Shave biopsies and electrodesiccation are inadequate; a full thickness of skin is essential for proper histologic diagnosis and classification. The most important prognostic indicator for stage I and II tumors is thickness; obtain a full-thickness biopsy specimen for adequate pathologic interpretation. Biopsy results ultimately determine the margins of resection and which patients are candidates for sentinel lymph node biopsy and other adjuvant treatment.

Patients who present with metastatic disease or with primary sites other than the skin have signs and symptoms related to the affected organ system(s).

Indications and Guidelines

Perform biopsy on all lesions suggestive of melanoma; sample the thickest part of the lesion. Maintain a low threshold to perform biopsy because the procedure is easy and safe. If the resection will not result in a disfiguring defect, excisional biopsy with a 2-mm skin margin and extension to the subcutaneous tissue is suggested for lesions less than 1.5 cm in diameter. Take care to leave scars in locations where re-excision is not difficult. If the lesion is large or located in an anatomic area where skin removal would cause disfigurement, an incisional biopsy may be performed. A full-thickness core punch biopsy in the most raised or irregular area is suggested, with the understanding that this area may not be the thickest area.

Contraindications

Biopsy of a suggestive lesion has no contraindications. Even with widely metastatic melanoma, local control can be attempted.

Relevant Anatomy

The skin is composed of multiple layers. The epidermis is the most superficial layer, and it contains keratinocytes in various stages of development. Melanocytes are located in the deepest layer of the epidermis. A basement membrane separates the epidermis from the underlying dermis, which is divided into 2 zones, papillary dermis and reticular dermis. Subcutaneous tissue is deep to the reticular dermis.

In 1874, Sappey performed an anatomic study of cutaneous lymphatic drainage, which is the foundation for current knowledge of this subject.3 Sappey's results demonstrated the lymphatic drainage based on anatomic location. His findings were modified later, but then the advent of lymphoscintigraphy led to more accurate lymphatic mapping. Norman et al then redefined the lymphatic basins in a definitive report.4 They concluded that an extensive overlap of basins drains the head, neck, shoulders, and trunk and that a specific basin cannot be predicted based on cutaneous location. Perform lymphoscintigraphy to define the exact lymphatic drainage for each patient.

Histologic Classification

Melanomas are classified into 4 major types based on growth pattern. They are superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. Other more unusual types include mucosal lentiginous melanoma, desmoplastic melanoma, and verrucous melanoma.

Superficial spreading melanoma

Superficial spreading melanomas constitute approximately 70% of melanomas. Histologically, the characteristic cells can be present singly or in nests along the dermal-epidermal junction, but they also may migrate into the stratum granulosum or stratum corneum. These cells can invade the papillary dermis with an inflammatory lymphocytic infiltrate.

Clinically, they usually arise in a preexisting dysplastic nevus.5,6 Typically, this lesion changes slowly over several months to years. They are usually flat but may become irregular and elevated in later stages. The lesions average 2 cm in diameter with variegated colors and peripheral notches, indentations, or both.

Nodular melanoma

Histology of nodular melanomas is characterized by extensive vertical growth into the dermis with a minimal radial component. They comprise approximately 15-30% of melanoma diagnoses. These tumors typically are blue-black but may lack pigment in some circumstances. They are known to arise without a preexisting lesion.

Lentigo maligna melanoma

Lentigo maligna melanomas represent 4-10% of melanomas. On a cellular level, dermal and epidermal changes from sun exposure must be present. The histologic appearance is one of irregularly shaped hyperchromatic cells that form spindle-shaped nests. The epidermis is atrophic, while the dermis contains solar elastosis with chronic inflammatory infiltrates. From a clinical standpoint, lentigo maligna melanomas are often larger than 3 cm, flat, tan, and begin as small, frecklelike lesions. They occur in sun-exposed areas (eg, face and neck of older individuals). Marked notching of the borders is present. Lentigo maligna melanoma usually arises within a Hutchinson freckle (lentigo maligna). When tumor thickness and location are taken into consideration, the prognosis for these melanomas is not believed to be worse than that for other subtypes.7

Acral lentiginous melanoma

This tumor comprises 2-8% of melanomas in whites and 35-60% of melanomas in dark-skinned people. Cellular proliferation is present along the dermal-epidermal junction with microinvasion into the papillary dermis. The cells have increased melanin granule production, which fills their dendritic extensions. Acral lentiginous melanomas occur on the palms of the hands, beneath the nail beds, and on the soles of the feet. They may appear on the palms and soles as flat, tan, or brown stains with irregular borders. Subungual lesions can be brown or black, with ulcerations in later stages. No correlation with a worse prognosis is demonstrated for these lesions when tumor thickness is considered.

Desmoplastic melanoma

These lesions account for approximately 1% of melanoma cases; they are fairly rare. They demonstrate a tendency for perineural invasion, especially in the head and neck. They have a propensity for higher local recurrence rates but lower regional metastasis rates.

Classification and Staging

Two classification schemes have been developed, based on either the vertical thickness of the lesion in millimeters or the anatomic level of invasion of the layers of skin. The Breslow classification scheme is used almost exclusively now because it more accurately predicts future tumor behavior. The Clark level is now used only in the staging of thin (T1) melanomas. The TNM (tumor, node, metastasis) system is used for clinical staging as designated by the American Joint Committee on Cancer (AJCC) staging system.8

  • Breslow classification
    • Thickness
      • Thickness of 0.75 mm or less
      • Thickness of 0.76-1.5 mm
      • Thickness of 1.51-4 mm
      • Thickness greater than 4 mm
  • Clark classification
    • Level I - Involves only epidermis (in situ melanoma); no invasion
    • Level II - Invades papillary dermis but not papillary-reticular dermal interface
    • Level III - Invades and expands papillary dermis up to the interface with, but not into, reticular dermis
    • Level IV - Invades reticular dermis but not into subcutaneous tissue
    • Level V - Invades into subcutaneous tissue
  • TNM staging
    • Primary tumor (pT)
      • pTX - Primary tumor cannot be assessed
      • pT0 - No evidence of primary tumor
      • pTis - Melanoma in situ; involves only epidermis (CL I)
      • pT1 - Tumor 1 mm or less in thickness; invades papillary dermis (CL II) (or to papillary-reticular dermal interface (CL III) (pT1b can mean that either the melanoma is £ 1 mm with ulceration or is <1 mm but is Clark level IV or V with or without ulceration.)
      • pT2 - Tumor 1.01-2 mm in thickness
      • pT3 - Tumor 2.01-4 mm in thickness
      • pT4 - Tumor greater than 4 mm in thickness and/or invades subcutaneous tissue (CL V) and/or satellite(s) within 2 cm of the primary tumor
      • pT4a - Tumor greater than 4 mm in thickness with or without ulceration
      • Any Ta - Not ulcerated
      • Any Tb - Ulcerated
    • Regional lymph nodes (N)
      • NX - Regional lymph nodes cannot be assessed
      • N0 - No regional lymph node metastasis
      • N1 - Metastasis in 1 lymph node
      • N2 - Metastasis in 2-3 lymph nodes or spread of melanoma in the skin toward a nearby lymph node area
      • N3 - Metastasis in 4 or more lymph nodes or spread of melanoma in the skin toward a lymph node area and into the lymph node(s)
      • Any Na - Melanoma only seen under the microscope
      • Any Nb - Melanoma in the lymph node visible to naked eye
    • Distant metastasis (M)
      • MX - Distant metastasis cannot be assessed
      • M0 - No distant metastasis
      • M1 - Distant metastasis
      • M1a - Metastases to skin or subcutaneous (below the skin) tissue or distant lymph nodes
      • M1b - Metastases to lung
      • M1c - Metastases to other organs
  • AJCC groupings8
    • Stage 0 (pTis, N0, M0): The melanoma is in situ, meaning that it involves the epidermis but has not spread to the dermis (lower layer).
    • Stage IA (pT1a, N0, M0): The melanoma is less than 1 mm in thickness and Clark level II or III. It is not ulcerated, appears to be localized in the skin, and has not been found in lymph nodes or distant organs.
    • Stage IB (pT1b or pT2a, N0, M0): The melanoma is less than 1 mm in thickness and is ulcerated or Clark level IV or V, or it is 1.01-2 mm and is not ulcerated. It appears to be localized in the skin and has not been found in lymph nodes or distant organs.
    • Stage IIA (pT2b or pT3a, N0, M0): The melanoma is 1.01-2 mm in thickness and is ulcerated, or it is 2.01-4 mm and is not ulcerated. It appears to be localized in the skin and has not been found in lymph nodes or distant organs.
    • Stage IIB (pT3b or pT4a, N0, M0): The melanoma is 2.01-4 mm in thickness and is ulcerated, or it is thicker than 4 mm and is not ulcerated. It appears to be localized in the skin and has not been found in lymph nodes or distant organs.
    • Stage IIC (pT4b, N0, M0): The melanoma is thicker than 4 mm and is ulcerated. It appears to be localized in the skin and has not been found in lymph nodes or distant organs.
    • Stage III (any pT, N1-3, M0): The melanoma has spread to lymph nodes near the affected skin area. No distant spread is present. The thickness of the melanoma is not a factor, although it is usually thick in people with stage III melanoma.
    • Stage IV (any pT, any N, any M1): The melanoma has spread beyond the original area of skin and nearby lymph nodes to other organs, such as the lungs, liver, or brain, or to distant areas of the skin or lymph nodes. Neither the lymph node status nor thickness is considered, but in general, the melanoma is thick and has spread to lymph nodes.

Treatment

Medical Therapy

Medical therapy is of questionable value; use it as adjuvant treatment in advanced stages.

Surgical Therapy

Surgical therapy for melanoma is based on the predicted risk of local recurrence and metastatic disease and the potential morbidity of the operation. If the lesion has not spread beyond the primary site, it is potentially curable. Most of these lesions are thin (<1 mm or CL I or II).

Stage 0

After making the diagnosis, widely excise the tumor or previous biopsy site. Use a 0.5- to 1-cm margin for melanomas in situ. No further therapy other than observation for nodal or recurrent disease is necessary.

Stage I

For a T1 lesion, 1-cm excision margins are adequate, but lesions greater than 1 mm require 2-cm margins. Studies demonstrate no improvement in recurrence or survival rates with larger margins of resection. Attempt primary closure and perform skin grafting or flap closure if necessary. For lesions with a depth greater than 1 mm, many authorities recommend sentinel lymph node biopsy at the time of wide local excision (see Stage II below).

Stage II

Perform a 2-cm surgical resection on stage II lesions. No recurrence or survival advantage is gained when 2-cm margins are compared with wider margins (4-6 cm). Smaller resection decreases the need for skin grafting and inpatient hospital stay.9

Perform a complete therapeutic lymphadenectomy on patients with suspected lymph node metastases based on physical examination findings. This consists of excision of all lymph nodes in the affected regional lymph node basin.

Consider sentinel lymph node biopsy if no clinically positive nodes are present. With the use of blue dye, radioisotope, or both, injected at the site of the primary melanoma, the first-echelon node can be identified within the regional lymph node basin. Send this sentinel node to the pathologist for analysis using routine stains, immunohistochemistry, and even polymerase chain reaction in some centers. If the sentinel node is positive, then regional lymph node metastases is probable; importantly, perform a complete lymph node dissection. The correlation is based on the thickness of the primary tumor. If the sentinel lymph node is negative, the chance is 99% that all others are negative. This procedure is becoming the standard of care for tumors greater than 1 mm in depth.

Hyperthermic arterial limb perfusion with melphalan for extremity melanomas has been studied as an adjuvant therapy. One study found it to be beneficial in that it produced higher response rates and overall survival rates than those for surgery alone. Other studies do not demonstrate benefit.

Adjuvant chemotherapy and/or biological therapy are also undergoing clinical evaluation. One study demonstrated that high-dose interferon alfa-2b resulted in prolonged relapse-free survival and overall survival compared with no adjuvant therapy. A follow-up study by the same group demonstrated preliminary results indicating high-dose interferon achieved a relapse-free survival benefit over no adjuvant treatment but not over low-dose interferon. Neither high- nor low-dose interferon had a significant overall survival advantage compared with observation alone. High-dose interferon can be associated with significant toxic/adverse effects (ie, liver toxicity), and some patients require dose reduction because it may not be well tolerated.

Stage III

Wide local excision of the primary tumor with 2-cm margins remains first-line therapy.10 No survival advantage is demonstrated with wider resection margins. Skin grafting or other tissue-transfer techniques may be necessary to close the defect. Perform regional lymph node dissection because a stage III melanoma represents nodal disease. If the nodal status is unknown, consider a sentinel lymph node biopsy to determine if the disease is stage I, II, or III. As in stage II disease, the treatment failure rate is higher with wide local excision alone in this group compared with stages 0 and I. Many clinical trials currently are exploring similar options as adjuvant therapy.

Stage IV

Advanced metastatic melanoma is usually refractory to standard therapy; thus, consider these patients for clinical trials. Some treatments have yielded various objective responses, although they are usually short-lived. Dacarbazine (DTIC) and the nitrosoureas, carmustine (BCNU) and lomustine (CCNU), produced a 20% objective response rate. Response rates for interferon alfa and interleukin 2 range from 8-22% and 10-20%, respectively. Currently, other studies in progress are comparing other cytotoxic and biologic drug regimens.

Surgical resection of isolated metastases in the gastrointestinal tract, the brain, the lungs, or bone may be performed for palliation, with occasional long survival. Metastatic lymph nodes also may be removed for palliation. Radiation may provide symptomatic relief for metastases to bone, the brain, or viscera. In-transit metastases arise in the lymphatics or soft tissue between the primary lesion and the regional lymph node basin at a rate of 2-3%. In addition to wide surgical excision as for a primary lesion, isolated hyperthermic limb perfusion is probably the most effective treatment for extremity lesions. Radiation and intralesional BCG vaccine injections have had varied success.

Recurrent melanoma

Surgical excision offers the most efficacious results in sites where it can be accomplished; however, melanoma is usually refractory to most standard systemic therapy.

Preoperative Details

Evaluate for metastases. Begin this evaluation with a detailed history and physical examination. The most common metastatic sites, in descending order, are the regional lymph nodes, skin and subcutaneous tissue (in-transit lesions), and lungs. Other possibilities include the brain, the liver, and bone.

In the absence of signs or symptoms of metastatic disease after performing the history and physical examination, obtain a chest radiograph. If abnormalities are observed, follow this with a chest CT scan.

Check serum alkaline phosphatase and lactate dehydrogenase levels. If these are abnormal or if the patient has a history of weight loss, anorexia, or abdominal pain, obtain a liver ultrasound, abdominal CT scan, or both.

Any abnormalities in the neurologic examination or a history of headaches, vertigo, numbness, or weakness warrant a head CT scan.

A bone scan also may be indicated for isolated bone pain or an elevated alkaline phosphatase level.

Use lymphoscintigraphy to identify the correct lymph node basin(s) that drain the site of the primary tumor. This is an essential aid in preoperative planning.

Intraoperative Details

When performing the wide local excision, first consider the surgical margins. If primary closure is not feasible, skin grafting or tissue transfers may be needed. The use of blue dye and radiotracer together provides excellent results and is sensitive in finding the sentinel lymph node. Frozen section specimens have largely been abandoned because the process destroys the ability to analyze the node using immunohistochemistry.

Postoperative Details

Send the lesion and lymph node specimens to experienced pathologists for review. After the primary tumor is evaluated, the lymph node(s) should undergo hematoxylin and eosin staining. If findings are negative for melanoma, use immunohistochemical techniques. Specific staining for S-100 protein and HMB-45 monoclonal antibody increases the detection of lymph node micrometastases. More elaborate techniques using reverse transcriptase polymerase chain reaction are still investigational. They can detect the tyrosinase gene, which is specific for the melanocyte.

Follow-up care

Close follow-up care is essential to monitor for new primary lesions, recurrence, or metastases. History and physical examination are the cornerstones, with further testing (eg, chest radiography, blood chemistries) if suggestive findings are encountered. Most practitioners observe patients every 3-6 months initially and then eventually decrease the frequency, although no consensus exists. Physicians observe patients with thicker tumors more frequently than patients with thinner lesions. Follow-up care with a dermatologist is strongly recommended. Educate patients on self-examination for detection of new or recurrent lesions and for recognition of the signs and symptoms of metastatic disease because the risk of developing a second melanoma or having recurrence is well recognized.

For excellent patient education resources, visit eMedicine's Cancer and Tumors Center and Procedures Center. Also, see eMedicine's patient education articles Skin Cancer, Skin Biopsy, and Mole Removal.

Complications, Prognosis, and Outcome

Complications

Inability to close the excision site primarily is not truly a complication; however, wound dehiscence, skin necrosis, or both can occur from closure under tension. Wound infection is a potential complication. Seromas and lymphoceles occur up to 27% of the time with axillary node dissection, while nerve dysfunction and/or pain can occur 22% of the time, and hematoma can occur 1% of the time. Lymphedema of the upper and lower extremities can complicate axillary and groin lymph node dissections. The rates vary from 2-39%. Avoid incomplete resection at all costs. Careful preoperative evaluation and meticulous attention to detail intraoperatively should help minimize the risk of these complications.

Prognosis

Poor prognostic factors include the following:

  • Tumor thickness (worse prognosis in thicker lesions)
  • Evidence of tumor in regional lymph nodes (stage III disease)
  • Higher number of positive lymph nodes
  • Presence of distant metastasis (stage IV disease)
  • Anatomic site (trunk and/or face lesions have worse prognoses than extremity lesions)
  • Presence of ulceration
  • Presence of regression on histologic examination (controversial)
  • Male sex

Outcome

The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed.

Relative survival rates take into consideration the fact that people may die of other causes besides melanoma. With relative rates, anyone who died of another cause, such as heart disease, is not counted. This is considered to be a more accurate way to describe the prognosis for people with particular types and stages of cancer. Of course, 5-year survival rates are based on patients diagnosed and initially treated more than 5 years ago. Improvements in treatment often result in a more favorable outlook for recently diagnosed patients.

  • Stage 0: The 5-year relative survival rate is 97%.
  • Stage I: The 5-year survival rate is 90-95%. If a sentinel node biopsy yields findings of melanoma in the lymph nodes, the 5-year survival is approximately 75%.
  • Stage IIA: The 5-year relative survival rate is approximately 85%. If a sentinel node biopsy yields findings of melanoma in the lymph nodes, the 5-year survival is approximately 65%.
  • Stage IIB: The 5-year relative survival rate is approximately 72-75%. If a sentinel node biopsy yields findings of melanoma in the lymph nodes, the 5-year survival is 50-60%.
  • Stage IIC: The 5-year relative survival rate is approximately 53%. If a sentinel node biopsy yields findings of melanoma in the lymph nodes, the 5-year survival is approximately 44%.
  • Stage III: The 5-year survival rate is approximately 45%. It is higher if the melanoma has spread to only one node and is lower if it has spread to more than 3. It is higher if the spread can only be seen under the microscope. It is lower if the melanoma was ulcerated.
  • Stage IV: The 5-year survival rate for stage IV melanoma is approximately 10%. It is higher if the spread was to skin or distant lymph nodes.

In a study from Alabama, patients with 1, 2-4, or more than 4 positive node(s) had survival rates of 58%, 27%, and 10%, respectively. Patients with spread to the lymph nodes have an 85% chance of developing occult disease. The worst outcome is predicted for patients with distant metastasis (stage IV). With a single metastatic site, the 1-year survival rate is 36%, but this drops to 13% with 2 sites. Patients with 3 or more sites of metastatic disease essentially have a 0% survival rate in the first year. These rates all vary somewhat according to the prognostic characteristics (see Prognosis).

Future and Controversies

The continuation of clinical trials to search for beneficial chemotherapy, gene therapy, biologic therapy, immunotherapy, and other adjunctive procedures is necessary to improve the prognosis for patients with melanoma. This is especially important as the number of patients continues to rise. As with all disease, methods for early detection in addition to careful physical examination are of utmost concern. Continued searches for serum markers and genetic markers are also essential. Creation of a successful public awareness campaign, such as those in Australia and New Zealand, is crucial.

Multimedia

Malignant melanoma. Courtesy of Hon Pak, MD.
(Enlarge Image)
Media file 1: Malignant melanoma. Courtesy of Hon Pak, MD.
[ CLOSE WINDOW ]
Malignant melanoma. Courtesy of Hon Pak, MD.

Malignant melanoma. Courtesy of Hon Pak, MD.

A 1.5-cm melanoma with characteristic asymmetry, ...
(Enlarge Image)
Media file 2: A 1.5-cm melanoma with characteristic asymmetry, irregular borders, and color variation. Courtesy of Wendy Brick, MD.
[ CLOSE WINDOW ]
A 1.5-cm melanoma with characteristic asymmetry, ...

A 1.5-cm melanoma with characteristic asymmetry, irregular borders, and color variation. Courtesy of Wendy Brick, MD.

Lentigo maligna melanoma, right lower cheek. Cent...
(Enlarge Image)
Media file 3: Lentigo maligna melanoma, right lower cheek. Centrally located erythematous papule represents invasive melanoma with surrounding macular lentigo maligna (melanoma in situ). Courtesy of Susan Swetter, MD.
[ CLOSE WINDOW ]
Lentigo maligna melanoma, right lower cheek. Cent...

Lentigo maligna melanoma, right lower cheek. Centrally located erythematous papule represents invasive melanoma with surrounding macular lentigo maligna (melanoma in situ). Courtesy of Susan Swetter, MD.

Keywords

skin malignancy, malignant melanoma, skin cancer, melanocytes, lentigo maligna melanoma, benign melanocytic nevi, benign melanocytic nevus, melanocytic nevi, melanocytic nevus, dysplastic nevi, dysplastic nevus, superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, mucosal lentiginous melanoma, desmoplastic melanoma, verrucous melanoma, sunburn

 


More on Skin Malignancies, Melanoma

References
[ CLOSE WINDOW ]

References

  1. American Cancer Society. What Are the Key Statistic About Melanoma? Detailed Guide: Skin Cancer – Melanoma. American Cancer Society Web site. Available at http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_melanoma_50.asp. Accessed September 26, 2008.

  2. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. Mar 1987;116(3):303-10. [Medline].

  3. Sappey MPC. Anatomie, physiologie, des vaisseaux lymphatique consideres chez l'homme et les vertebras. Paris;1874.

  4. Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. Nov 1991;162(5):432-7. [Medline].

  5. Marghoob AA, Kopf AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with ''classic'' atypical-mole syndrome. A case-control study. Arch Dermatol. Aug 1994;130(8):993-8. [Medline].

  6. Kraemer KH, Tucker M, Tarone R, et al. Risk of cutaneous melanoma in dysplastic nevus syndrome types A and B. N Engl J Med. Dec 18 1986;315(25):1615-6. [Medline].

  7. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol. Sep 1984;2(9):994-1001. [Medline].

  8. American Joint Committee on Cancer. Malignant melanoma of the skin. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1997:163-70.

  9. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. Sep 1993;218(3):262-7; discussion 267-9. [Medline].

  10. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. Jun 1998;5(4):322-8. [Medline].

  11. Ames FC, Singletary SE. Cutaneous malignancies of the trunk and lower extremities. In: Johnson DE, Ames FC, eds. Atlas of Groin Dissection. Chicago, Ill: Year Book Medical; 1985:111-36.

  12. Armstrong BK, English DR. Epidemiologic studies. In: Balch CM, Milton GW, Soong S-J, et al, eds. Cutaneous Melanoma. 2nd ed. Philadelphia, Pa: Lippincott; 1992:12.

  13. Bakotic B, Ackerman AB. Staging of melanoma: a critique in historical perspective: part I. Am J Dermatopathol. Apr 2005;27(2):160-4. [Medline].

  14. Balch CM, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol. Jan 1996;14(1):1-3. [Medline].

  15. Balch CM, Milton GW. Diagnosis of metastatic melanoma at distant sites. In: Balch CM, Milton GW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia, Pa: Lippincott; 1985:221-50.

  16. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. Feb 1983;1(2):126-34. [Medline].

  17. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. Mar 1981;193(3):377-88. [Medline].

  18. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. Nov 1970;172(5):902-8. [Medline].

  19. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. Jan 15 1995;75(2):478-94. [Medline].

  20. Clark WH Jr, Ainsworth AM, Bernardino EA, et al. The developmental biology of primary human malignant melanomas. Semin Oncol. Jun 1975;2(2):83-103. [Medline].

  21. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. Mar 1969;29(3):705-27. [Medline].

  22. Coit DG. Patient surveillance and follow-up. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 3rd ed. St. Louis, Mo: Quality Medical; 1998.

  23. Cormier JN, Davidson L, Xing Y, et al. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol. Mar-Apr 2005;3(2):139-45. [Medline].

  24. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. Apr 1 2005;[Medline].

  25. Davis J, Pack GT, Higgins GK. Melanotic freckle of Hutchinson. Am J Surg. Apr 1967;113(4):457-63. [Medline].

  26. Evans GR, Manson PN. A variation in the appearance of melanoma-in-situ (Clark's level I malignant melanoma). Plast Reconstr Surg. Sep 1994;94(3):513-7. [Medline].

  27. Evans GR, Manson PN. Review and current perspectives of cutaneous malignant melanoma. J Am Coll Surg. May 1994;178(5):523-40. [Medline].

  28. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer. Aug 9 1995;62(4):377-81. [Medline].

  29. Friedman RJ, Rigel DS, Kopf AW. Early detection of cutaneous melanoma: The role of physician examination and self-examination of the skin. Atlanta, Ga: American Cancer Society; 1985.

  30. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. Jun 1998;16(6):2253-60. [Medline].

  31. Glocker-Reis LA, Miller BA, Hankey BF, eds. SEER Cancer Statistics Review, 1973-1991. National Cancer Institute. Bethesda, Md: National Institutes of Health Publication; 1994:2789.

  32. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol. Dec 1991;9(12):2091-4. [Medline].

  33. Heasley DD, Toda S, Mihm MC Jr. Pathology of malignant melanoma. Surg Clin North Am. Dec 1996;76(6):1223-55. [Medline].

  34. Herbert SH, Solin LJ, Rate WR, et al. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma. Cancer. May 15 1991;67(10):2472-6. [Medline].

  35. Ho VC, Sober AJ, Balch CM. Biopsy techniques. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 3rd ed. St. Louis, Mo: Quality Medical; 1998.

  36. Huffman TA, Sterin WK. Ten-year survival with multiple metastatic malignant melanoma. Primary site unknown. Arch Surg. Feb 1973;106(2):234-5. [Medline].

  37. Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. Sep 1996;3(5):446-52. [Medline].

  38. Karakousis CP, Douglass HO Jr, Yeracaris PM, Holyoke ED. BCG immunotherapy in patients with malignant melanoma. Arch Surg. Jun 1976;111(6):716-8. [Medline].

  39. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma. Ann Surg Oncol. Jul 1994;1(4):271-7. [Medline].

  40. Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma. Am J Surg. Sep 1991;162(3):202-7. [Medline].

  41. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. Jun 2000;18(12):2444-58. [Medline].

  42. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. Jan 1996;14(1):7-17. [Medline].

  43. Krementz ET, Feed RJ, Coleman WP 3d, et al. Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg. May 1982;195(5):632-45. [Medline].

  44. Krementz ET, Ryan RF, Carter RD, et al. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Milton GW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia, Pa: JB Lippincott; 1985:171-95.

  45. Kung JX, Ackerman AB. Staging of melanoma: a critique of the most recent (2002) system proposed by the American Joint Committee on Cancer: part II. Am J Dermatopathol. Apr 2005;27(2):165-7. [Medline].

  46. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. Jan-Feb 1999;49(1):8-31, 1. [Medline].

  47. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. Sep 1991;78(9):1108-10. [Medline].

  48. Legha SS. Current therapy for malignant melanoma. Semin Oncol. Feb 1989;16(1 Suppl 1):34-44. [Medline].

  49. Liu T, Soong SJ. Epidemiology of malignant melanoma. Surg Clin North Am. Dec 1996;76(6):1205-22. [Medline].

  50. Magnus K. Habits of sun exposure and risk of malignant melanoma: An analysis of incidence rates in Norway. In: Magnus K. Trends in Cancer Incidence. Washington, DC: Hemisphere; 1982:387.

  51. Mansfield PF, Ames FC, Balch CM. Axillary lymph node dissection. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 3rd ed. St. Louis, Mo: Quality Medical; 1998.

  52. McGovern VJ, Shaw HM, Milton GW. Histogenesis of malignant melanoma with an adjacent component of the superficial spreading type. Pathology. Apr 1985;17(2):251-4. [Medline].

  53. Messina JL. Pathologic examination of sentinel lymph nodes. Techniques 2000. 1996.

  54. Mihm MC Jr, Fitzpatrick TB, Brown MM, et al. Early detection of primary cutaneous malignant melanoma. A color atlas. N Engl J Med. Nov 8 1973;289(19):989-96. [Medline].

  55. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. Apr 1992;127(4):392-9. [Medline].

  56. National Institutes of Health. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. Sep 9 1992;268(10):1314-9. [Medline].

  57. Nectoux J. Time trends: Malignant melanoma of the skin. In: Magnus K. Trends in Cancer Incidence. Washington, DC: Hemisphere; 1982:365.

  58. Perez IR, Fenske NA, Brozena SJ. Malignant melanoma: differential diagnosis of the pigmented lesion. Semin Surg Oncol. May-Jun 1993;9(3):168-73. [Medline].

  59. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. May 1991;9(5):729-35. [Medline].

  60. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys. Oct 1988;15(4):859-64. [Medline].

  61. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. Dec 1994;220(6):759-67. [Medline].

  62. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. May 1996;34(5 Pt 1):839-47. [Medline].

  63. Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer. May 1 1996;77(9):1809-14. [Medline].

  64. Ritchie AC. Boyd's Textbook of Pathology. Vol 2. Philadelphia, Pa: Lea & Febiger; 1990:2037.

  65. Schwartz SI. Principles of Surgery. 7th ed. New York, NY: McGraw-Hill; 1999:527.

  66. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA Cancer J Clin. Jan-Feb 1990;40(1):9-26. [Medline].

  67. Singletary SE, Shallenberger R, Guinee VF, McBride CM. Melanoma with metastasis to regional axillary or inguinal lymph nodes: prognostic factors and results of surgical treatment in 714 patients. South Med J. Jan 1988;81(1):5-9. [Medline].

  68. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. Oct 1993;11(10):1969-77. [Medline].

  69. Stadelmann WK, McMasters K, Digenis AG, Reintgen DS. Cutaneous melanoma of the head and neck: advances in evaluation and treatment. Plast Reconstr Surg. May 2000;105(6):2105-26. [Medline].

  70. Stadelmann WK, Rappaport DP, Soong S-J, et al. Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 3rd ed. St. Louis, Mo: Quality Medical; 1998:11-35.

  71. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr. Dec 1985;68:161-89. [Medline].

  72. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. Jun 1 1982;49(11):2420-30. [Medline].

  73. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. Apr 1991;126(4):438-41. [Medline].

  74. Wagner JD, Gordon MS, Chuang TY, Coleman JJ 3rd. Current therapy of cutaneous melanoma. Plast Reconstr Surg. Apr 2000;105(5):1774-99; quiz 1800-1. [Medline].

  75. Wells KE, Reintgen DS, Cruse CW. The current management and prognosis of acral lentiginous melanoma. Ann Plast Surg. Jan 1992;28(1):100-3. [Medline].

  76. Wick MM, Sober AJ, Fitzpatrick TB, et al. Clinical characteristics of early cutaneous melanoma. Cancer. May 15 1980;45(10):2684-6. [Medline].

  77. Wong JH, Skinner KA, Kim KA, et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery. Apr 1993;113(4):389-94. [Medline].

  78. Wornom IL 3d, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. Aug 1986;204(2):181-5. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

skin malignancy, malignant melanoma, skin cancer, melanocytes, lentigo maligna melanoma, benign melanocytic nevi, benign melanocytic nevus, melanocytic nevi, melanocytic nevus, dysplastic nevi, dysplastic nevus, superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, mucosal lentiginous melanoma, desmoplastic melanoma, verrucous melanoma, sunburn

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Jonathan B Heistein, MD, Private Practice, Plastic and Reconstructive Surgery
Jonathan B Heistein, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Plastic Surgeons, Texas Medical Association, and Texas Society of Plastic Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Robert L Ruberg, MD, Chair, Professor, Department of Surgery, Division of Plastic Surgery, Ohio State University College of Medicine
Robert L Ruberg, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for the Surgery of Trauma, American Association of Plastic Surgeons, American Burn Association, American Cleft Palate/Craniofacial Association, American College of Surgeons, American Medical Association, American Society for Aesthetic Plastic Surgery, Association for Academic Surgery, Central Surgical Association, Ohio State Medical Association, Pan American Medical Association, Phi Beta Kappa, and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Shahin Javaheri, MD, Chief, Department of Plastic Surgery, Martinez Veterans Affairs Outpatient Clinic; Consulting Staff, Advanced Aesthetic Plastic & Reconstructive Surgery
Shahin Javaheri, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery and American Society of Plastic Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Jorge I de la Torre, MD, FACS, Professor of Surgery and Physical Medicine and Rehabilitation, Residency Program Director, Division of Plastic Surgery, University of Alabama at Birmingham; Director, Center for Advanced Surgical Aesthetics
Jorge I de la Torre, MD, FACS is a member of the following medical societies: American Association of Plastic Surgeons, American Burn Association, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Society for Reconstructive Microsurgery, American Society of Maxillofacial Surgeons, American Society of Plastic Surgeons, Association for Academic Surgery, and Medical Association of the State of Alabama
Disclosure: Nothing to disclose.

CME Editor

Nicolas (Nick) G Slenkovich, MD, Practice Director, Colorado Plastic Surgery Center at Swedish Medical Center
Nicolas (Nick) G Slenkovich, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, American Society of Plastic Surgeons, and Colorado Medical Society
Disclosure: Nothing to disclose.

Chief Editor

Jorge I de la Torre, MD, FACS, Professor of Surgery and Physical Medicine and Rehabilitation, Residency Program Director, Division of Plastic Surgery, University of Alabama at Birmingham; Director, Center for Advanced Surgical Aesthetics
Jorge I de la Torre, MD, FACS is a member of the following medical societies: American Association of Plastic Surgeons, American Burn Association, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Society for Reconstructive Microsurgery, American Society of Maxillofacial Surgeons, American Society of Plastic Surgeons, Association for Academic Surgery, and Medical Association of the State of Alabama
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.